Amarin Corp Plc (AMRN)

[BioChica]

I think their concept is based on: Vascepa is unsafe if used in place of other approved drugs for CVD i.e. Statin. Because we the FDA have no proof that Vascpa works. Yet the expanded Anchor label is for use with a Statin, not to replace it. So they sound confused about the Anchor label marketing approval Amarin was after in the first place.

They are using reverse logic to define safety! :>)